Department of Medicine, Cecil G. Sheps Center for Health Services Research, and Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599, USA.
J Gen Intern Med. 2012 Jun;27 Suppl 1(Suppl 1):S83-93. doi: 10.1007/s11606-011-1898-z.
In this paper, we discuss common challenges in and principles for conducting systematic reviews of genetic tests. The types of genetic tests discussed are those used to 1). determine risk or susceptibility in asymptomatic individuals; 2). reveal prognostic information to guide clinical management in those with a condition; or 3). predict response to treatments or environmental factors. This paper is not intended to provide comprehensive guidance on evaluating all genetic tests. Rather, it focuses on issues that have been of particular concern to analysts and stakeholders and on areas that are of particular relevance for the evaluation of studies of genetic tests. The key points include: The general principles that apply in evaluating genetic tests are similar to those for other prognostic or predictive tests, but there are differences in how the principles need to be applied or the degree to which certain issues are relevant. A clear definition of the clinical scenario and an analytic framework is important when evaluating any test, including genetic tests. Organizing frameworks and analytic frameworks are useful constructs for approaching the evaluation of genetic tests. In constructing an analytic framework for evaluating a genetic test, analysts should consider preanalytic, analytic, and postanalytic factors; such factors are useful when assessing analytic validity. Predictive genetic tests are generally characterized by a delayed time between testing and clinically important events. Finding published information on the analytic validity of some genetic tests may be difficult. Web sites (FDA or diagnostic companies) and gray literature may be important sources. In situations where clinical factors associated with risk are well characterized, comparative effectiveness reviews should assess the added value of using genetic testing along with known factors compared with using the known factors alone. For genome-wide association studies, reviewers should determine whether the association has been validated in multiple studies to minimize both potential confounding and publication bias. In addition, reviewers should note whether appropriate adjustments for multiple comparisons were used.
本文讨论了系统评价遗传检测时常见的挑战和原则。所讨论的遗传检测类型包括:1)用于确定无症状个体的风险或易感性;2)为有病症的人提供预后信息以指导临床管理;或 3)预测对治疗或环境因素的反应。本文并非旨在提供评估所有遗传检测的全面指南。相反,它侧重于分析人员和利益相关者特别关注的问题,以及评估遗传检测研究特别相关的领域。要点包括:评估遗传检测时适用的一般原则与其他预后或预测性检测的原则相似,但在应用这些原则的方式或某些问题的相关性方面存在差异。在评估任何检测时,包括遗传检测,明确临床情况和分析框架非常重要。组织框架和分析框架是评估遗传检测的有用构建。在构建评估遗传检测的分析框架时,分析人员应考虑分析前、分析中和分析后的因素;这些因素在评估分析有效性时很有用。预测性遗传检测的特点通常是检测与临床重要事件之间存在延迟时间。可能难以找到某些遗传检测分析有效性的已发表信息。网站(FDA 或诊断公司)和灰色文献可能是重要的信息来源。在与风险相关的临床因素得到很好描述的情况下,比较有效性评价应评估使用遗传检测与使用已知因素相结合与单独使用已知因素相比的附加值。对于全基因组关联研究,审查人员应确定关联是否已在多个研究中得到验证,以最大程度地减少潜在的混杂和发表偏倚。此外,审查人员应注意是否使用了适当的多重比较调整。